Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Fludarabine + Cyclophosphamide + Rituximab (FCR)
Treatment for Chronic lymphoid leukemia
Typical Dosage: Fludarabine 25mg/m2 IV, Cyclophosphamide 250mg/m2 IV, Rituximab 375mg/m2 IV (all on specific days of a 28-day cycle)
Effectiveness
80%
Safety Score
28%
Clinical Trials
35
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
28
DangerousModerateSafe
Treatment Details
Dosage Range
Fludarabine 25mg/m2 IV, Cyclophosphamide 250mg/m2 IV, Rituximab 375mg/m2 IV (all on specific days of a 28-day cycle)
Time to Effect
3-6 months
Treatment Duration
6 cycles (approx. 6 months)
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$10,000
Side Effect Mgmt:$15,000
Total Annual:$65,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTQALYs Gained
0.8
Outcome-Based Costs
Cost per Responder
$81,250
Cost per Remission
$162,500
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
2 active trials recruiting for Fludarabine + Cyclophosphamide + Rituximab (FCR) in Chronic lymphoid leukemia
A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL
NCT03980002RECRUITINGPHASE2
50 participants
INTERVENTIONAL
Tianjin, China
Started: May 15, 2019
A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL
NCT02158091ACTIVE NOT RECRUITINGPHASE1, PHASE2
32 participants
INTERVENTIONAL
Boston, United States +1 more
Started: Jun 27, 2014
Completed Clinical Trials
13 completed trials for Fludarabine + Cyclophosphamide + Rituximab (FCR) in Chronic lymphoid leukemia
Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
NCT01723839COMPLETEDPHASE2
21 participants
INTERVENTIONAL
Hackensack, United States
Started: Feb 22, 2012
FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
NCT00448019COMPLETEDPHASE2
64 participants
INTERVENTIONAL
Houston, United States
Started: Feb 1, 2007
Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00868413COMPLETEDPHASE1
32 participants
INTERVENTIONAL
La Jolla, United States +5 more
Started: Nov 1, 2009
Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP
NCT00564512COMPLETEDPHASE3
178 participants
INTERVENTIONAL
Rouen, France
Started: Nov 1, 2007
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
NCT00381004COMPLETEDPHASE2
60 participants
INTERVENTIONAL
Houston, United States
Started: Sep 1, 2006
Intensified Rituimab Prephase Before FCR in Untreated B-CLL
NCT01370772COMPLETEDPHASE2
140 participants
INTERVENTIONAL
Rouen, France +1 more
Started: May 1, 2011
A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL
NCT00772486COMPLETEDPHASE1
13 participants
INTERVENTIONAL
San Diego, United States
Started: Sep 1, 2008
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00759798COMPLETEDPHASE2
289 participants
INTERVENTIONAL
Houston, United States
Started: Aug 13, 2008
Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline
NCT00794820COMPLETEDPHASE2
66 participants
INTERVENTIONAL
Houston, United States
Started: Dec 1, 2003
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
NCT04285567COMPLETEDPHASE3
166 participants
INTERVENTIONAL
Aurora, United States +39 more
Started: May 28, 2020
A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT02533401COMPLETEDPHASE2
34 participants
INTERVENTIONAL
Buenos Aires, Argentina +8 more
Started: Feb 1, 2006
Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia
NCT00275054COMPLETEDPHASE3
825 participants
INTERVENTIONAL
Vienna, Austria +90 more
Started: Oct 1, 2005
FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia
NCT00769522COMPLETEDPHASE3
564 participants
INTERVENTIONAL
Cologne, Germany
Started: Oct 2, 2008
Showing 20 of 35 total trials